MX2016015181A - Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. - Google Patents

Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.

Info

Publication number
MX2016015181A
MX2016015181A MX2016015181A MX2016015181A MX2016015181A MX 2016015181 A MX2016015181 A MX 2016015181A MX 2016015181 A MX2016015181 A MX 2016015181A MX 2016015181 A MX2016015181 A MX 2016015181A MX 2016015181 A MX2016015181 A MX 2016015181A
Authority
MX
Mexico
Prior art keywords
agonist
combination
treating cancer
ccr4 antibody
antibody
Prior art date
Application number
MX2016015181A
Other languages
English (en)
Spanish (es)
Inventor
Chia-Yang Lin
Chen Shihao
Fen Lee Li
Potluri Shobha
HEALY Denis
Marshall Margaret
Sawada Naoki
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016015181A publication Critical patent/MX2016015181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016015181A 2014-05-21 2015-05-15 Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. MX2016015181A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462001534P 2014-05-21 2014-05-21
PCT/US2015/031081 WO2015179236A1 (en) 2014-05-21 2015-05-15 Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer

Publications (1)

Publication Number Publication Date
MX2016015181A true MX2016015181A (es) 2017-05-25

Family

ID=53284562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015181A MX2016015181A (es) 2014-05-21 2015-05-15 Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.

Country Status (12)

Country Link
US (1) US10023649B2 (OSRAM)
EP (1) EP3145956A1 (OSRAM)
JP (1) JP2017517506A (OSRAM)
KR (1) KR20170004006A (OSRAM)
CN (1) CN106413751A (OSRAM)
AU (1) AU2015264528A1 (OSRAM)
BR (1) BR112016026993A2 (OSRAM)
CA (1) CA2949214A1 (OSRAM)
IL (1) IL248540A0 (OSRAM)
MX (1) MX2016015181A (OSRAM)
RU (1) RU2016146993A (OSRAM)
WO (1) WO2015179236A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105979961B (zh) * 2014-02-05 2020-12-18 西达-赛奈医疗中心 用于治疗癌症和感染性疾病的方法和组合物
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
EP3408294A1 (en) * 2016-01-25 2018-12-05 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
IL300095A (en) * 2016-11-23 2023-03-01 Translational Drug Dev Llc Benzamide and tumor necrosis factor receptor superfamily agonist compositions and uses thereof
AU2018206015B2 (en) 2017-01-06 2019-05-30 Eutilex Co., Ltd. Anti-human 4-1 BB antibodies and use thereof
EP3431105B1 (en) 2017-03-29 2020-01-01 Shionogi&Co., Ltd. Medicinal composition for treating cancer
JP7657023B2 (ja) 2017-06-09 2025-04-04 プロビデンス ヘルス アンド サービシーズ－オレゴン がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用
EP3652209A2 (en) 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonist antibodies that bind human cd137 and uses thereof
WO2019072274A1 (zh) * 2017-10-12 2019-04-18 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
CN109651507B (zh) 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019090272A1 (en) 2017-11-06 2019-05-09 Flx Bio, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019109238A1 (en) * 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
EP3744734A1 (en) * 2018-01-22 2020-12-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
MX2020009468A (es) * 2018-03-13 2020-10-22 Hoffmann La Roche Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
US12054554B2 (en) 2018-04-10 2024-08-06 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP7682102B2 (ja) 2019-05-10 2025-05-23 リビジェン バイオファーマ ホールディングス リミテッド ヒト化抗ｃｄ１３７抗体およびその使用
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
KR20220127859A (ko) * 2020-01-13 2022-09-20 사이토딘 인크. Ccr5 양성 전이성 암 치료를 위한 ccr5 결합제
CN115135344A (zh) * 2020-02-04 2022-09-30 健玛保 在疗法中使用的抗体
BR112022014623A2 (pt) * 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
EP4228627A4 (en) * 2020-10-13 2024-11-06 Board of Regents, The University of Texas System COMBINATORIAL IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PANCREATIC DUCT ADENOCARCINOMA
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
IL309856A (en) 2021-07-14 2024-02-01 Genentech Inc Antibodies anti-C-C motif receptor 8 (CCR8) and methods of use
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
CN1296960A (zh) * 1999-11-22 2001-05-30 上海博容基因开发有限公司 一种新的多肽——人ccr4相关蛋白31和编码这种多肽的多核苷酸
DK1449850T3 (da) 2001-08-31 2011-02-14 Kyowa Hakko Kirin Co Ltd Humane CDR-graftede antistoffer eller antistoffragmenter deraf
CA2492561A1 (en) * 2002-07-15 2004-01-22 Mayo Foundation For Medical Education And Research Treatment and prophylaxis with 4-1bb-binding agents
EP1702625B1 (en) 2003-12-04 2010-11-03 Kyowa Hakko Kirin Co., Ltd. Medicine containing genetically modified antibody against chemokine receptor ccr4
GB0409799D0 (en) * 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
CA2588157A1 (en) 2004-11-17 2006-05-26 Board Of Regents, The University Of Texas System Cancer immunotherapy incorporating p53
EP1851244A4 (en) * 2005-02-15 2009-04-15 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
EP1896030A1 (en) 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20

Also Published As

Publication number Publication date
WO2015179236A1 (en) 2015-11-26
RU2016146993A (ru) 2018-06-21
US10023649B2 (en) 2018-07-17
IL248540A0 (en) 2016-12-29
CA2949214A1 (en) 2015-11-26
AU2015264528A1 (en) 2016-11-03
BR112016026993A2 (pt) 2017-10-31
US20170088627A1 (en) 2017-03-30
KR20170004006A (ko) 2017-01-10
CN106413751A (zh) 2017-02-15
EP3145956A1 (en) 2017-03-29
JP2017517506A (ja) 2017-06-29

Similar Documents

Publication Publication Date Title
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX378273B (es) Compuestos activos hacia bromodominios.
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
IL276733A (en) Use of Aribolin in cancer treatment
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
IL247586A0 (en) Use of Aribolin and mtor inhibitors as a combined treatment for cancer
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
PH12016501938A1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
IL269769B (en) Compounds, composition and uses thereof for treating cancer
HK1242990A1 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
GB2546703A (en) Compounds
UA100460U (uk) Застосування препарату ноофен як засобу лікування еректильної дисфункції в моно- або комплексній терапії
UA88729U (uk) Спосіб консервативного лікування хронічного геморою